There are three anti-IL-17 monoclonal antibody agents which have approved by the US Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis: secukinumab [36] and ixekizumab [37] (IL-17 A antagonists), and brodalumab [38] (IL-17RA antagonist). Here, IL17A is linked to psoriasis vulgaris.